Published in ChemMedChem on January 09, 2013
The CARLSBAD database: a confederated database of chemical bioactivities. Database (Oxford) (2013) 1.05
Monoselective o-C-H Functionalizations of Mandelic Acid and α-Phenylglycine. J Am Chem Soc (2015) 0.75
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev (2001) 36.00
How many drug targets are there? Nat Rev Drug Discov (2006) 14.22
Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem (2002) 6.85
Ligand efficiency: a useful metric for lead selection. Drug Discov Today (2004) 6.60
ZINC: a free tool to discover chemistry for biology. J Chem Inf Model (2012) 6.57
New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem (2010) 6.54
The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov (2007) 6.27
Natural products in drug discovery. Drug Discov Today (2008) 4.46
Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry. J Chem Inf Comput Sci (2003) 2.90
The impact of natural products upon modern drug discovery. Curr Opin Chem Biol (2008) 2.84
Structural basis of perturbed pKa values of catalytic groups in enzyme active sites. IUBMB Life (2002) 2.25
Probing the links between in vitro potency, ADMET and physicochemical parameters. Nat Rev Drug Discov (2011) 2.12
Can we rationally design promiscuous drugs? Curr Opin Struct Biol (2006) 2.06
Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. ACS Chem Neurosci (2010) 2.06
Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. J Med Chem (2007) 2.02
Generation of a set of simple, interpretable ADMET rules of thumb. J Med Chem (2008) 1.99
Disease-induced changes in the plasma binding of basic drugs. Clin Pharmacokinet (1980) 1.92
Strategic pooling of compounds for high-throughput screening. J Chem Inf Comput Sci (1999) 1.44
Pharmacological promiscuity: dependence on compound properties and target specificity in a set of recent Roche compounds. ChemMedChem (2009) 1.42
Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. Chem Res Toxicol (2011) 1.35
The influence of the 'organizational factor' on compound quality in drug discovery. Nat Rev Drug Discov (2011) 1.32
Plasma and tissue protein binding of drugs in pharmacokinetics. Drug Metab Rev (1976) 1.22
Fragments, network biology and designing multiple ligands. Drug Discov Today (2006) 1.22
Modeling promiscuity based on in vitro safety pharmacology profiling data. ChemMedChem (2007) 1.21
An analysis of the binding efficiencies of drugs and their leads in successful drug discovery programs. J Med Chem (2010) 1.20
The pK(a) Distribution of Drugs: Application to Drug Discovery. Perspect Medicin Chem (2007) 1.14
Drug- and lead-likeness, target class, and molecular diversity analysis of 7.9 million commercially available organic compounds provided by 29 suppliers. J Chem Inf Model (2010) 1.00
Critical Compilation of pK(a) Values for Pharmaceutical Substances. Profiles Drug Subst Excip Relat Methodol (2007) 0.98
Factor Xa inhibitors: next-generation antithrombotic agents. J Med Chem (2010) 0.97
Construction of a sequence motif characteristic of aminergic G protein-coupled receptors. Protein Sci (2003) 0.92
hERG-related drug toxicity and models for predicting hERG liability and QT prolongation. Expert Opin Drug Metab Toxicol (2009) 0.90
Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential. J Chem Inf Model (2007) 0.90
Design of compound libraries for fragment screening. J Comput Aided Mol Des (2009) 0.83
The acid-base profile of a contemporary set of drugs: implications for drug discovery. SAR QSAR Environ Res (2009) 0.81
Chemogenomics in drug discovery. Ernst Schering Res Found Workshop (2006) 0.81
Human ether-a-go-go related gene (HERG): a chemist's perspective. Prog Med Chem (2005) 0.80
Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol (2006) 5.20
Estrogen signaling through the transmembrane G protein-coupled receptor GPR30. Annu Rev Physiol (2008) 3.20
G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res (2007) 2.71
In vivo effects of a GPR30 antagonist. Nat Chem Biol (2009) 2.39
Pursuing the leadlikeness concept in pharmaceutical research. Curr Opin Chem Biol (2004) 2.36
A crowdsourcing evaluation of the NIH chemical probes. Nat Chem Biol (2009) 2.29
Distribution and characterization of estrogen receptor G protein-coupled receptor 30 in the rat central nervous system. J Endocrinol (2007) 2.20
Quantifying the relationships among drug classes. J Chem Inf Model (2008) 1.92
Drug Repurposing from an Academic Perspective. Drug Discov Today Ther Strateg (2011) 1.68
BDDCS applied to over 900 drugs. AAPS J (2011) 1.68
An automated PLS search for biologically relevant QSAR descriptors. J Comput Aided Mol Des (2005) 1.66
Interactive exploration of chemical space with Scaffold Hunter. Nat Chem Biol (2009) 1.55
Bradycardic effects mediated by activation of G protein-coupled estrogen receptor in rat nucleus ambiguus. Exp Physiol (2012) 1.51
QSAR modeling of the blood-brain barrier permeability for diverse organic compounds. Pharm Res (2008) 1.46
Identification of a GPER/GPR30 antagonist with improved estrogen receptor counterselectivity. J Steroid Biochem Mol Biol (2011) 1.42
Integration of virtual screening with high-throughput flow cytometry to identify novel small molecule formylpeptide receptor antagonists. Mol Pharmacol (2005) 1.37
The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells. Cancer Res (2010) 1.36
The ins and outs of GPR30: a transmembrane estrogen receptor. J Steroid Biochem Mol Biol (2008) 1.36
Associating Drugs, Targets and Clinical Outcomes into an Integrated Network Affords a New Platform for Computer-Aided Drug Repurposing. Mol Inform (2011) 1.35
Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations. Antivir Ther (2004) 1.35
Optimization of CAMD techniques 3. Virtual screening enrichment studies: a help or hindrance in tool selection? J Comput Aided Mol Des (2008) 1.32
Relationship between antimalarial activity and heme alkylation for spiro- and dispiro-1,2,4-trioxolane antimalarials. Antimicrob Agents Chemother (2008) 1.28
Novel chemical space exploration via natural products. J Med Chem (2009) 1.27
GPR30: a novel therapeutic target in estrogen-related disease. Trends Pharmacol Sci (2008) 1.25
Characterization of a Cdc42 protein inhibitor and its use as a molecular probe. J Biol Chem (2013) 1.24
High-throughput screening with HyperCyt flow cytometry to detect small molecule formylpeptide receptor ligands. J Biomol Screen (2005) 1.22
Intracellular cannabinoid type 1 (CB1) receptors are activated by anandamide. J Biol Chem (2011) 1.20
ChemProt-2.0: visual navigation in a disease chemical biology database. Nucleic Acids Res (2012) 1.17
A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields. J Med Chem (2011) 1.17
In vitro differentiation of human mesenchymal stem cells to epithelial lineage. J Cell Mol Med (2007) 1.16
High-throughput flow cytometry to detect selective inhibitors of ABCB1, ABCC1, and ABCG2 transporters. Assay Drug Dev Technol (2008) 1.14
Rapid evaluation of synthetic and molecular complexity for in silico chemistry. J Chem Inf Model (2005) 1.13
Expression of estrogen receptor GPR30 in the rat spinal cord and in autonomic and sensory ganglia. J Neurosci Res (2009) 1.11
Bioactivity-guided mapping and navigation of chemical space. Nat Chem Biol (2009) 1.11
Modulation of bitter taste perception by a small molecule hTAS2R antagonist. Curr Biol (2010) 1.09
Iron-mediated degradation kinetics of substituted dispiro-1,2,4-trioxolane antimalarials. J Pharm Sci (2007) 1.09
Biomolecular screening of formylpeptide receptor ligands with a sensitive, quantitative, high-throughput flow cytometry platform. Nat Protoc (2006) 1.07
Potent and long-acting dimeric inhibitors of influenza virus neuraminidase are effective at a once-weekly dosing regimen. Antimicrob Agents Chemother (2004) 1.05
The CARLSBAD database: a confederated database of chemical bioactivities. Database (Oxford) (2013) 1.05
ChemProt: a disease chemical biology database. Nucleic Acids Res (2010) 1.03
Scaffold topologies. 2. Analysis of chemical databases. J Chem Inf Model (2008) 1.02
A three-dimensional model of the human immunodeficiency virus type 1 integration complex. J Comput Aided Mol Des (2005) 1.02
Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen. Mol Cancer Ther (2007) 1.01
Estrogen rapidly modulates 5-hydroxytrytophan-induced visceral hypersensitivity via GPR30 in rats. Gastroenterology (2009) 1.00
Kinetics of iron-mediated artemisinin degradation: effect of solvent composition and iron salt. J Pharm Sci (2005) 1.00
Activation of dioxin response element (DRE)-associated genes by benzo(a)pyrene 3,6-quinone and benzo(a)pyrene 1,6-quinone in MCF-10A human mammary epithelial cells. Toxicol Appl Pharmacol (2007) 0.98
Discovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties. J Med Chem (2011) 0.98
Emerging trends in the discovery of natural product antibacterials. Curr Opin Pharmacol (2013) 0.97
Strategies for compound selection. Curr Drug Discov Technol (2004) 0.95
High-throughput screening for daunorubicin-mediated drug resistance identifies mometasone furoate as a novel ABCB1-reversal agent. J Biomol Screen (2008) 0.95
Virtual screening applications: a study of ligand-based methods and different structure representations in four different scenarios. J Comput Aided Mol Des (2007) 0.95
Identification of a small molecule yeast TORC1 inhibitor with a multiplex screen based on flow cytometry. ACS Chem Biol (2012) 0.95
High-throughput flow cytometry for drug discovery. Expert Opin Drug Discov (2007) 0.95
2-aminothienopyridazines as novel adenosine A1 receptor allosteric modulators and antagonists. J Med Chem (2008) 0.94
iPHACE: integrative navigation in pharmacological space. Bioinformatics (2010) 0.93
Scaffold topologies. 1. Exhaustive enumeration up to eight rings. J Chem Inf Model (2008) 0.93
Thiazolidinedione-based PI3Kα inhibitors: an analysis of biochemical and virtual screening methods. ChemMedChem (2011) 0.93
Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev (2011) 0.92
Duplex high-throughput flow cytometry screen identifies two novel formylpeptide receptor family probes. Cytometry A (2009) 0.92
A competitive nucleotide binding inhibitor: in vitro characterization of Rab7 GTPase inhibition. ACS Chem Biol (2012) 0.92
Homology modeling and docking evaluation of aminergic G protein-coupled receptors. J Chem Inf Model (2010) 0.92
Mechanisms of G protein-coupled estrogen receptor-mediated spinal nociception. J Pain (2012) 0.91
G protein-coupled estrogen receptor 1-mediated effects in the rat myometrium. Am J Physiol Cell Physiol (2011) 0.90
Transporter-mediated Efflux Influences CNS Side Effects: ABCB1, from Antitarget to Target. Mol Inform (2010) 0.90
Self-assembly behavior of colistin and its prodrug colistin methanesulfonate: implications for solution stability and solubilization. J Phys Chem B (2010) 0.90
High-throughput screen for the chemical inhibitors of antiapoptotic bcl-2 family proteins by multiplex flow cytometry. Assay Drug Dev Technol (2011) 0.89
BDDCS class prediction for new molecular entities. Mol Pharm (2012) 0.89
Parallel screening of low molecular weight fragment libraries: do differences in methodology affect hit identification? J Biomol Screen (2012) 0.89
Fluorescent substrates for flow cytometric evaluation of efflux inhibition in ABCB1, ABCC1, and ABCG2 transporters. Anal Biochem (2013) 0.88
Microbial efflux pump inhibition: tactics and strategies. Curr Pharm Des (2011) 0.88
Virtual screening using a conformationally flexible target protein: models for ligand binding to p38α MAPK. J Comput Aided Mol Des (2012) 0.88
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. Assay Drug Dev Technol (2010) 0.87
Detection of intracellular granularity induction in prostate cancer cell lines by small molecules using the HyperCyt high-throughput flow cytometry system. J Biomol Screen (2009) 0.87
An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus. J Med Chem (2003) 0.86
Oncology exploration: charting cancer medicinal chemistry space. Drug Discov Today (2006) 0.86
Degradation of berenil (diminazene aceturate) in acidic aqueous solution. J Pharm Pharmacol (2004) 0.85
Discovery of selective probes and antagonists for G-protein-coupled receptors FPR/FPRL1 and GPR30. Curr Top Med Chem (2009) 0.85
A novel flow cytometric HTS assay reveals functional modulators of ATP binding cassette transporter ABCB6. PLoS One (2012) 0.85
Conformational mAb as a tool for integrin ligand discovery. Assay Drug Dev Technol (2009) 0.84
Model-free drug-likeness from fragments. J Chem Inf Model (2010) 0.84
Digestion of phospholipids after secretion of bile into the duodenum changes the phase behavior of bile components. Mol Pharm (2014) 0.84
The leukocyte chemotactic receptor FPR2, but not the closely related FPR1, is sensitive to cell-penetrating pepducins with amino acid sequences descending from the third intracellular receptor loop. Biochim Biophys Acta (2013) 0.84
Crystal structure of the HIV-1 integrase core domain in complex with sucrose reveals details of an allosteric inhibitory binding site. FEBS Lett (2010) 0.84
Probing the fibrate binding specificity of rat liver fatty acid binding protein. J Med Chem (2009) 0.84
Descriptor collision and confusion: toward the design of descriptors to mask chemical structures. J Comput Aided Mol Des (2005) 0.83
Quantum chemical study of the intermediate complex required for iron-mediated reactivity and antimalarial activity of dispiro-1,2,4-trioxolanes. J Mol Graph Model (2008) 0.83
Cross-pharmacology analysis of G protein-coupled receptors. Curr Top Med Chem (2011) 0.83
Discovery of a novel selective PPARγ ligand with partial agonist binding properties by integrated in silico/in vitro work flow. J Chem Inf Model (2013) 0.83
A selective ATP-binding cassette subfamily G member 2 efflux inhibitor revealed via high-throughput flow cytometry. J Biomol Screen (2012) 0.82
Preparation and in vitro evaluation of novel lipopeptide transfection agents for efficient gene delivery. Bioconjug Chem (2008) 0.82
The significance of acid/base properties in drug discovery. Chem Soc Rev (2013) 0.82